{"id":"NCT00658788","sponsor":"Galderma R&D","briefTitle":"Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis","officialTitle":"A Multi-Center, Open-Label Study to Evaluate the Safety and Efficacy of a Consecutive Treatment Regimen of Clobetasol Propionate 0.05% Spray, Followed by Calcitriol Ointment 3µg/g, in the Management of Moderate to Severe Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-03","primaryCompletion":"2009-01","completion":"2009-01","firstPosted":"2008-04-15","resultsPosted":"2014-08-27","lastUpdate":"2022-08-23"},"enrollment":305,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"clobetasol propionate spray 0.05%","otherNames":["Clobex® Spray 0.05%"]},{"type":"DRUG","name":"calcitriol ointment","otherNames":[]}],"arms":[{"label":"Study Treatment","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objectives of this study are to evaluate the safety \\& efficacy of consecutive treatments of Clobex® Spray and Silkis® Ointment in the management of plaque psoriasis.","primaryOutcome":{"measure":"Overall Disease Severity Success (ODS)","timeFrame":"8 and 12 weeks","effectByArm":[{"arm":"Sequential Treatment Regimen","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":12,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":305},"commonTop":[]}}